RESUMO
Cyclotron-produced L-(N-13)glutamate was used to visualize malignant intracranial tumors in 12 pediatric patients who had evidence of recurrent disease as documented by computed transaxial tomography (TCT). Imaging was performed using a rectilinear scanner, gamma camera, or a positron-emission tomograph (PET). The results indicate that N-13 is rapidly taken up by a majority of brain tumors following the administration of L-(N-13)glutamate, and that N-13 uptake is correlated with breakdown of the blood-brain barrier as demonstrated by contrast TCT or pertechnetate (Tc-99m) studies. The feasibility of using this agent in conjunction with PET is established.
Assuntos
Neoplasias Encefálicas/diagnóstico por imagem , Glutamatos , Radioisótopos de Nitrogênio , Tomografia Computadorizada de Emissão/métodos , Adolescente , Adulto , Barreira Hematoencefálica , Criança , Feminino , Ácido Glutâmico , Humanos , Masculino , Pertecnetato Tc 99m de Sódio , Tecnécio , Tomografia Computadorizada por Raios XRESUMO
In normal volunteers and cancer patients, studies using L-(N-13)glutamate as an imaging agent showed localization of N-13 activity in the heart. Other organs that were well visualized include the liver, pancreas, and salivary glands. In ten subjects the average myocardial uptake after intravenous injection of labeled glutamate was (5.7 +/- 0.39)% (s.e.m.) of injected dose, as determined by a quantitative scanning system. The concentration of N-13 activity in the human heart could not be predicted from previous studies involving myocardial uptake in dogs and rodents after administration of L-(N-13)glutamate.
